Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MOREAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS). AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Without treatment, average survival time after infection with HIV is estimated to be 9 to 11 years, depending on the HIV subtype. Infection with HIV occurs by the transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk. Within these bodily fluids, HIV is present as both free virus particles and virus within infected immune cells. HIV infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages, and dendritic cells. HIV infection leads to low levels of CD4+ T cells through a number of mechanisms, including pyroptosis of abortively infected T cells, apoptosis of uninfected bystander cells, direct viral killing of infected cells, and killing of infected CD4+ T cells by CD8 cytotoxic lymphocytes that recognize infected cells. When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections.
Gp41 also known as glycoprotein 41 is a subunit of the envelope protein complex of retroviruses, including human immunodeficiency virus (HIV). Gp41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells.Env is a viral gene that encodes the protein forming the viral envelope. The expression of the env gene enables retroviruses to target and attach to specific cell types, and to infiltrate the target cell membrane.Env is a viral gene that encodes the protein forming the viral envelope. The expression of the env gene enables retroviruses to target and attach to specific cell types, and to infiltrate the target cell membrane.
Loading...
| CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
| CAR-T-2-LX364 | Anti-HIV (8062) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 8062 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-T-2-LX370 | Anti-HIV (HK20) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | HK20 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-T-2-LX397 | Anti-HIV (VRC42.04) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | VRC42.04 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-T-2-LX405 | Anti-HIV (13H11) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 13H11 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-T-2-LX429 | Anti-HIV (8062) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 8062 | Human | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-T-2-LX435 | Anti-HIV (HK20) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | HK20 | Human | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-T-2-LX462 | Anti-HIV (VRC42.04) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | VRC42.04 | Human | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-T-2-LX470 | Anti-HIV (13H11) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 13H11 | Human | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-T-2-LX490 | Anti-HIV (Z13e) (CD4-scFv-h(CD28-CD3ζ)) CAR, pCDCAR1 | Human | Z13e | Human | CD4-scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-T-2-LX560 | Anti-HIV (F240) (CD4-scFv-h(CD28-CD3ζ)) CAR, pCDCAR1 | Human | F240 | Human | CD4-scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-T-2-LX589 | Anti-HIV (8066) (CD4-scFv-h(CD28-CD3ζ)) CAR, pCDCAR1 | Human | 8066 | Human | CD4-scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-T-2-LX609 | Anti-HIV (DH570) (CD4-scFv-h(CD28-CD3ζ)) CAR, pCDCAR1 | Human | DH570 | Macaque | CD4-scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-T-2-LX610 | Anti-HIV (DH570.4) (CD4-scFv-h(CD28-CD3ζ)) CAR, pCDCAR1 | Human | DH570.4 | Macaque | CD4-scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-T-2-LX623 | Anti-HIV (11F10) (CD4-scFv-h(CD28-CD3ζ)) CAR, pCDCAR1 | Human | 11F10 | Mouse | CD4-scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-T-2-LX624 | Anti-HIV (6a7) (CD4-scFv-h(CD28-CD3ζ)) CAR, pCDCAR1 | Human | 6a7 | Mouse | CD4-scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-T-2-LX711 | Anti-HIV (13H11) (CD4-scFv-h(CD28-CD3ζ)) CAR, pCDCAR1 | Human | 13H11 | Human | CD4-scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
| CAR-T-2-LX731 | Anti-HIV (Z13e) (CD4-scFv-h(4-1BB-CD3ζ)) CAR, pCDCAR1 | Human | Z13e | Human | CD4-scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-T-2-LX732 | Anti-HIV (17b) (CD4-scFv-h(4-1BB-CD3ζ)) bNAb CAR, pCDCAR1 | Human | 17b | Human | CD4-scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-T-2-LX801 | Anti-HIV (F240) (CD4-scFv-h(4-1BB-CD3ζ)) CAR, pCDCAR1 | Human | F240 | Human | CD4-scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | ||
| CAR-T-2-LX850 | Anti-HIV (DH570) (CD4-scFv-h(4-1BB-CD3ζ)) CAR, pCDCAR1 | Human | DH570 | Macaque | CD4-scFv-4-1BB-CD3ζ | Lentiviral vector | T cell |
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
